VERFAHREN ZUR HERSTELLUNG VON 2-HALOGENINDAN-1-ONEN
申请人:Bayer Aktiengesellschaft
公开号:EP1007498A1
公开(公告)日:2000-06-14
SUBSTITUTED ANILINIC PIPERIDINES AS MCH SELECTIVE ANTAGONISTS
申请人:Synaptic Pharmaceutical Corporation
公开号:EP1411942A1
公开(公告)日:2004-04-28
EP1411942A4
申请人:——
公开号:EP1411942A4
公开(公告)日:2005-01-26
[DE] VERFAHREN ZUR HERSTELLUNG VON 2-HALOGENINDAN-1-ONEN<br/>[EN] PROCESS FOR PREPARING 2-HALOGENATED INDAN-1-ONES<br/>[FR] PROCEDE DE PREPARATION DE 2-HALOGENE INDANE-1-ONES
申请人:——
公开号:WO1999010306A1
公开(公告)日:1999-03-04
[EN] In an advantageous 2-halogenated indan-1-one production process, anilines are transformed into diazonium salts, which are then reacted with acryl compounds to produce 3-phenyl-1-halogenated propionic acid derivatives, and the latter are annulated. [FR] L'invention concerne des 2-halogène indane-1-ones qui s'obtiennent de manière avantageuse par transformation d'anilines en sels de diazonium qui sont à leur tour mis à réagir avec des composés acryliques pour donner lieu à des dérivés de 3-phényle-1-acide halogène propionique, ces derniers étant cyclisés. [DE] 2-Halogenindan-1-one werden in vorteilhafter Weise hergestellt, wnn man Aniline in Diazoniumsalze überführt, diese mit Acrylverbindungen in 3-Phenyl-1-halogenpropionsäurederivate und letztere cyclisiert.
[EN] SUBSTITUTED ANILINIC PIPERIDINES AS MCH SELECTIVE ANTAGONISTS<br/>[FR] PIPERIDINES ANILINIQUES SUBSTITUEES, UTILISEES COMME ANTAGONISTES SELECTIFS DE LA MCH
申请人:SYNAPTIC PHARMA CORP
公开号:WO2003004027A1
公开(公告)日:2003-01-16
This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier.